About Us
As a healthcare growth equity firm, we seek to deliver strong returns in both healthcare and life sciences and strive to make an impact on the industry by driving positive change for patients and communities worldwide.
We are a Healthcare Growth Equity Firm
EW Healthcare Partners is a healthcare growth equity firm that has been pursuing and supporting growth companies since 1985. With strategically located investment offices in New York, London, and Houston, we share a global perspective and an understanding of the evolving healthcare landscape.
Backed by our team’s extensive experience in various industries, we meticulously review potential investment opportunities to determine the ones that we believe deserve further due diligence. Through collective efforts, we identify and pursue such growth equity investments, specifically involving Pharmaceuticals, MedTech, and Tech-Enabled Services.
Our Extensive Experience
Our team of investors bring together years of combined health care experience and domain expertise.
Our areas of expertise include operational, strategic, regulatory, financing, research and development, and HR matters.
Our vast network of key stakeholders includes healthcare providers, industry leaders, and research institutions.
Our Differentiated Approach
How are we different from other healthcare growth equity firms?
We have deep domain experience – healthcare investing is our only business. Healthcare is a highly specialized industry and EW believes specialists in healthcare are better suited to manage the regulatory and reimbursement environment.
We focus on revenue-generating companies with significant growth potential.
We partner with successful management teams and help them excel.
We invest in companies based in the United States and Europe and help our portfolio companies expand internationally and sell their products globally.
Ryan Marcotte
“Enercon is excited to partner with EW Healthcare for the next stage of our company’s growth,” said Ryan Marcotte, CEO at Enercon Technologies. “EW enhances Enercon’s already strong financial and operational position by providing expertise in Enercon’s core end markets of Healthcare and MedTech. EW shares our vision of growing Enercon as a platform and they align with our values and culture that our employees are our most important asset. We are thrilled to have EW as our partner.”
Tony Koblish
“I have worked across two companies with EW as largest shareholder with great success. EW offers tremendous depth, experience, and passion for building top-shelf MedTech companies that help surgeons help patients. EW partners with management in a truly value added collaboration process with competency and mutual respect. I consider EW a top investment partner.”
Peter Van Haur
“EW has become a trusted partner as we work to grow the VitalConnect business. The expertise, insights and extensive relationships they have brought have been instrumental across multiple aspects of diligence, commercialization and funding which has allowed us to grow shareholder value together.”
Ted Davis
“The EW team has been a terrific partner for us at BioTissue. In addition to EW’s expertise and commitment to the regenerative medicine space, the firm has an intentional approach of bringing specific skill sets to each portfolio company. EW’s Board representation includes operating perspective and financial/investment expertise, which provides a robust foundation for our Board as we drive our strategic transformation at BioTissue. Shaunak and Bob have been great partners for our Founders, our co-investors and our management team, willing to simply weigh in as a sounding board or “roll up their sleeves” when needed.”
Joseph Capper
“EW Healthcare has been a trusted partner of ours for several years, and we appreciate their support in working toward a shared vision of patient-centered innovation in healthcare. In my time as CEO at MIMEDX, the team at EW has offered valuable strategic counsel at the board level and contributed meaningfully to our growth story.”
Morris Miller
“We are thrilled to partner with EW. With their understanding of the medical device space and how companies should operate, EW has added value from ‘Day 1’. We were very impressed with the careful diligence conducted by the EW team, and we look forward to a great future together!”
Nancy Lurker
“I am so pleased with our working relationship and the experience, guidance and support that EW provides to EyePoint Pharmaceuticals. The quality of their input, at both the Board level and the management level, has been superb and we have forged a true partnership.”
Karen Zaderej
“The EW team is extremely knowledgeable, and their ability to identify great innovations and market opportunities, and help move those innovations forward by sharing expertise and assisting in business plan execution is remarkable. AxoGen is proud to have Essex as a partner in our continued growth.”
Bryan Morton
“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA.”
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.
Our Global Reach
We are well-positioned to seize global opportunities and identify strategic investments.
We make global investments in the healthcare industry. Currently, we are active in the United States and Europe. Through strategic allocation of resources and leveraging our international presence, we aim to maximize success and deliver value to shareholders.
Our focus lies in pursuing opportunities arising from the increasing demand for enhanced healthcare, innovative technology, and improved healthcare products. The drivers of this growth are clear and largely consistent ~ an aging population, increasing prevalence of chronic diseases, a rapidly growing middle class, and continued adoption of innovative technologies and therapies.